BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020

Investors looking for something of a safe haven in the COVID-19 storm might like BioMarin Pharmaceutical (NASDAQ:BMRN). While most stocks have languished in 2020, the biotech's shares are up 12% so far this year.

BioMarin could pick up even more momentum now. The company announced its first-quarter results after the market closed on Wednesday. Here are the highlights from BioMarin's Q1 update.